
BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

China lays focus on age-related cognitive decline

September 1, 2021 | News

Insilico Medicine collaborates with Gray Matter



China-based Insilico Medicine has announced an R&D collaboration with Gray Matter, a longevity biotechnology company focused on peptide-based interventions against cognitive decline, age-related CNS diseases, and aging.

This strategic partnership is intended to speed up the discovery of new therapeutic targets for peptide therapy in the field of age-related cognitive decline and involve Insilico Medicine's AI-augmented platforms and close cooperation between the Gray Matter and Insilico Medicine scientists.

The prevalence of mild cognitive impairment (MCI) rises from 6.7% (1 in every 14 people) for ages 60–64 to 25.2% (1 in every four people) for the 80–84 cohort. People diagnosed with MCI are 3-5 times more likely to develop dementia of some form.

"We aim to develop a new generation of safe and effective therapies to help patients live longer, healthier lives with their cognition intact. We see a remarkable synergy between our rapid iterative approach based on proprietary peptide discovery engine Reptide and AI-powered target discovery by Insilico Medicine. This collaboration is intended to help Gray Matter further to reduce costs and timeline for early drug development," said Alexey Strygin, co-founder and CEO of Gray Matter.